$PCRX

2 Stocks Drawing Bearish Options Activity Today

Pacira BioSciences (PCRX) rose 44% to $36.30 after Viatris (VTRS) agreed to acquire it for $36.50 per share, valuing the deal at $1.65B. Despite the rally, options activity is bearish. Ring Energy (REI) also saw unusual options volume amid a price increase.

Original reporting
Published Oct 8, 2026, 3:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 3:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
2 Stocks Drawing Bearish Options Activity Today — source image
Decision brief

The 30-second read

$PCRXBullishHigh
01

Why it matters

The Pacira acquisition is a material event likely to move the stock, while Ring Energy's options flow signals market caution.

02

Market read

The buyout drives a sharp rally in PCRX, while bearish options on REI hint at potential downside, offering short‑term trading opportunities.

03

What to watch

Regulatory approval risk for the Viatris‑Pacira transaction could delay or derail the deal.

Relevance 9/10Novelty 9/10Timing: today

Background

The article highlights two stocks with notable options activity, focusing on a major acquisition and unusual bearish positioning.

Company-level read

Ticker impact

$PCRXBullishHigh confidence
Context

Viatris announced a $1.65B cash acquisition of Pacira at $36.50 per share, sending PCRX up 44% and triggering heavy bearish options volume.

Expected impact

likely short‑term downside pressure as traders hedge the rally

Evidence & confidence

The deal is a material M&A event; the stock has already surged, and the dominant bearish delta indicates traders expect a pull‑back.

$REIBearishMedium confidence
Context

Options traders posted unusually high bearish volume on Ring Energy despite the stock trading higher today.

Expected impact

potential near‑term price pressure

Evidence & confidence

No fundamental catalyst is cited; the bearish options signal market skepticism.

Market effects

The pharma M&A may spur further consolidation activity in the specialty drug space.

US biotech sector sees heightened volatility as the deal unfolds.

Large‑cap M&A adds to overall market breadth, influencing risk sentiment.

Counterpoint

Despite the buyout premium, the high price may already price in the deal, and bearish options suggest a pull‑back.

Key entities

  • Viatris Inc.

    Acquirer of Pacira BioSciences in a $1.65B cash deal.

  • Pacira BioSciences Inc.

    Target of the Viatris acquisition.

  • Ring Energy Inc.

    Energy producer with elevated bearish options volume.

Related articles

$VTRSHighAI 9/10

Viatris to Acquire Pacira in US$1.65bn Pain Management Deal

Viatris (VTRS) announced plans to acquire Pacira BioSciences (PCRX) for approximately US$1.65bn. Pacira generated US$746m in revenue over the last 12 months. The deal aims to strengthen Viatris' portfolio in non-opioid pain management, adding Pacira's Exparel and Zilretta to its offerings. The acquisition is expected to be immediately accretive and is set to close by the end of 2026.

$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

$VTRSHighAI 9/10

Viatris to Acquire Pacira Biosciences for USD 1.65 Billion, Adds Exparel, Zilretta to Pain Portfolio

Viatris (VTRS) will acquire Pacira Biosciences (PCRX) for $1.65B, or $36.50 per share, a 44.8% premium. Pacira shares rose 44%, Viatris fell 2%. The deal adds Exparel and Zilretta to Viatris' pain portfolio, with 2025 sales of $575.1M and $116.6M. Viatris plans to fund the deal with cash and short-term borrowings, expecting minimal leverage impact and immediate accretion.